• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

玻璃体内注射阿柏西普治疗高度视网膜色素上皮脱离

[Intravitreal aflibercept in high retinal pigment epithelial detachments].

作者信息

Boriskina L N, Khzardzhan Yu Yu, Zotov A S, Balalin A S, Kuznetsova N V

机构信息

Volgograd branch of S. Fyodorov Eye Microsurgery Federal State Institution, 80 Zemlyachki St., Volgograd, Russian Federation, 400138.

出版信息

Vestn Oftalmol. 2018;134(5):92-98. doi: 10.17116/oftalma201813405192.

DOI:10.17116/oftalma201813405192
PMID:30499545
Abstract

PURPOSE

To study the effectiveness of intravitreal aflibercept in high pigment epithelium detachment (PED) in eyes with age-related macular degeneration (AMD).

MATERIAL AND METHODS

This study included 16 eyes of 16 patients (10 female and 6 male) aged 52 to 82 years (mean age 68.56±2.31 years). Examination of patients included determination of best-corrected visual acuity (BCVA), biomicroscopy with Goldmann lens, photographic recording of the ocular fundus, optical coherence tomography (OCT) and OCT-angiography. Results of the treatment were evaluated 1 month after the third injection of aflibercept. Among the analyzed parameters were: BCVA, maximum PED height, resorption of perifocal neuroepithelium detachment (NED), expressiveness of hyperreflective content of PED.

RESULTS

One months into the treatment, after the third injection, mean BCVA improved by 0.09 to 0.36±0.04, height of PED decreased in average by 225.3±44.6 µm to 326.88±25.13 µm. Complete resolution of PED was not achieved in any of the cases. Resulting mean height of perifocal PED was 61.25±12.87 µm. Full resorption of PED was achieved in 4 eyes. Expressiveness of hyperreflective content of PED higher than 50% was observed in 13 eyes (81.25%).

CONCLUSION

The results of intravitreal aflibercept in AMD patients with high PED have proved its effectiveness in reducing maximum PED height, improving resorption of perifocal NED and BCVA. Optically 'empty' PEDs had higher sensitivity to intravitreal aflibercept than hyperreflective PEDs. Statistically significant dependence of BCVA on the height and content of PED was absent.

摘要

目的

研究玻璃体内注射阿柏西普治疗年龄相关性黄斑变性(AMD)患者高色素上皮脱离(PED)的有效性。

材料与方法

本研究纳入了16例患者的16只眼(10例女性,6例男性),年龄在52至82岁之间(平均年龄68.56±2.31岁)。对患者的检查包括最佳矫正视力(BCVA)测定、使用戈德曼接触镜进行生物显微镜检查、眼底照相记录、光学相干断层扫描(OCT)和OCT血管造影。在第三次注射阿柏西普1个月后评估治疗结果。分析的参数包括:BCVA、最大PED高度、黄斑周围神经上皮脱离(NED)的吸收情况、PED高反射成分的表现。

结果

治疗1个月后,第三次注射后,平均BCVA提高了0.09至0.36±0.04,PED高度平均下降了225.3±44.6 µm至326.88±25.13 µm。所有病例均未实现PED的完全消退。黄斑周围PED的最终平均高度为61.25±12.87 µm。4只眼实现了PED的完全吸收。13只眼(81.25%)观察到PED高反射成分的表现高于50%。

结论

玻璃体内注射阿柏西普治疗高PED的AMD患者的结果证明了其在降低最大PED高度、改善黄斑周围NED的吸收和BCVA方面的有效性。光学上“空的”PED对玻璃体内注射阿柏西普的敏感性高于高反射性PED。BCVA与PED的高度和成分之间不存在统计学上的显著相关性。

相似文献

1
[Intravitreal aflibercept in high retinal pigment epithelial detachments].玻璃体内注射阿柏西普治疗高度视网膜色素上皮脱离
Vestn Oftalmol. 2018;134(5):92-98. doi: 10.17116/oftalma201813405192.
2
Prospective PED-study of intravitreal aflibercept for refractory vascularized pigment epithelium detachment due to age-related macular degeneration: morphologic characteristics of non-responders in optical coherence tomography.前瞻性 PED 研究:玻璃体内阿柏西普治疗年龄相关性黄斑变性导致的难治性血管化色素上皮脱离:光学相干断层扫描中无应答者的形态学特征。
Graefes Arch Clin Exp Ophthalmol. 2020 Jul;258(7):1411-1417. doi: 10.1007/s00417-020-04675-y. Epub 2020 Apr 18.
3
Clinical response of pigment epithelial detachment associated with neovascular age-related macular degeneration in switching treatment from Ranibizumab to Aflibercept.在从雷珠单抗转换为阿柏西普治疗时,与新生血管性年龄相关性黄斑变性相关的色素上皮脱离的临床反应
BMC Ophthalmol. 2018 Jun 22;18(1):148. doi: 10.1186/s12886-018-0824-0.
4
WRINKLED VASCULARIZED RETINAL PIGMENT EPITHELIUM DETACHMENT PROGNOSIS AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.玻璃体内抗血管内皮生长因子治疗后皱襞状血管化视网膜色素上皮脱离的预后。
Retina. 2018 Jun;38(6):1100-1109. doi: 10.1097/IAE.0000000000001698.
5
Aflibercept for pigment epithelial detachment for previously treated neovascular age-related macular degeneration.阿柏西普用于治疗既往已接受治疗的新生血管性年龄相关性黄斑变性所致的色素上皮脱离
Can J Ophthalmol. 2015 Oct;50(5):373-7. doi: 10.1016/j.jcjo.2014.12.012. Epub 2015 Aug 12.
6
Response of vascular pigment epithelium detachment due to age-related macular degeneration to monthly treatment with ranibizumab: the prospective, multicentre RECOVER study.雷珠单抗每月治疗年龄相关性黄斑变性所致血管性色素上皮脱离的疗效:前瞻性、多中心RECOVER研究
Acta Ophthalmol. 2017 Nov;95(7):683-689. doi: 10.1111/aos.13359. Epub 2017 Jan 13.
7
Comparison of anti-VEGF therapies on fibrovascular pigment epithelial detachments in age-related macular degeneration.抗VEGF疗法对年龄相关性黄斑变性中纤维血管性色素上皮脱离的疗效比较
Br J Ophthalmol. 2017 Jul;101(7):970-975. doi: 10.1136/bjophthalmol-2016-309434. Epub 2016 Dec 2.
8
Ranibizumab versus aflibercept for the treatment of vascularized pigment epithelium detachment due to age-related macular degeneration.雷珠单抗与阿柏西普治疗年龄相关性黄斑变性所致血管化色素上皮脱离的疗效比较
Int Ophthalmol. 2019 Feb;39(2):431-440. doi: 10.1007/s10792-018-0833-2. Epub 2018 Feb 5.
9
PIGMENT EPITHELIAL DETACHMENT RESPONSE TO AFLIBERCEPT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION REFRACTORY TO RANIBIZUMAB: Time Course and Drug Effects.阿柏西普治疗对雷珠单抗耐药的新生血管性年龄相关性黄斑变性患者色素上皮脱离的反应:时间进程和药物效应
Retina. 2016 May;36(5):881-8. doi: 10.1097/IAE.0000000000000813.
10
Factors Influencing the Treatment Response of Pigment Epithelium Detachment in Age-Related Macular Degeneration.影响年龄相关性黄斑变性中色素上皮脱离治疗反应的因素
Am J Ophthalmol. 2015 Oct;160(4):732-8.e2. doi: 10.1016/j.ajo.2015.06.025. Epub 2015 Jul 2.